Skip to main content

Advertisement

SpringerLink
Log in

Metabolic risks in older adults receiving second-generation antipsychotic medication

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Metabolic syndrome is prevalent in older adults and increases the risk of cardiovascular disease. Second-generation antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone) increase the risk of metabolic syndrome and present many challenges for psychiatrists. In this article, we review the relationships between second-generation antipsychotics and metabolic syndrome with a focus on older adults. Because few studies focus exclusively on older adults, we augment this review with relevant findings from younger adults. The differential risk factors of each medication are reviewed, as are recent findings in monitoring and treating metabolic syndrome. Olanzapine and clozapine are more strongly associated with metabolic risks, whereas aripiprazole and ziprasidone are less associated. Although lifestyle modifications can help to reduce some aspects of metabolic syndrome, lifestyle modifications in conjunction with metformin therapy appear to be most effective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Park Y, Zhu S, Palaniappan L, et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003, 163:427–436.

    Article  PubMed  Google Scholar 

  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

  3. Hildrum B, Mykletun A, Hole T, et al.: Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health 2007, 7:220.

    Article  PubMed  Google Scholar 

  4. Ishizaka N, Ishizaka Y, Toda E, et al.: Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 2005, 28:27–34.

    Article  PubMed  Google Scholar 

  5. Cankurtaran M, Halil M, Yavuz BB, et al.: Prevalence and correlates of metabolic syndrome (MS) in older adults. Arch Gerontol Geriatr 2006, 42:35–45.

    Article  PubMed  CAS  Google Scholar 

  6. De Hert M, Schreurs V, Sweers K, et al.: Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008, 101:295–303.

    Article  PubMed  Google Scholar 

  7. Bauer M, Pfennig A: Epidemiology of bipolar disorders. Epilepsia 2005, 46:8–13.

    Article  PubMed  Google Scholar 

  8. Depp CA, Jeste DV: Bipolar disorder in older adults: a critical review. Bipolar Disord 2004, 6:343–367.

    Article  PubMed  Google Scholar 

  9. Henderson AS, Korten AE, Levings C, et al.: Psychotic symptoms in the elderly: a prospective study in a population sample. Int J Geriatr Psychiatry 1998, 13:484–492.

    Article  PubMed  CAS  Google Scholar 

  10. Saha S, Chant D, Welham J, McGrath J: A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.

    Article  PubMed  Google Scholar 

  11. Straker D, Correll CU, Kramer-Ginsberg E, et al.: Costeffective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005, 162:1217–1221.

    Article  PubMed  Google Scholar 

  12. Sicras A, Rejas J, Navarro R, et al.: Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008, 10:607–616.

    Article  PubMed  CAS  Google Scholar 

  13. McEvoy JP, Meyer JM, Goff DC, et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19–32.

    Article  PubMed  Google Scholar 

  14. Allison DB, Mentore JL, Heo M, et al.: Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686–1696.

    PubMed  CAS  Google Scholar 

  15. Rege S: Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008, 42:369–381.

    PubMed  Google Scholar 

  16. Baskin ML, Ard J, Franklin F, Allison DB: Prevalence of obesity in the United States. Obes Rev 2005, 6:5–7.

    Article  PubMed  CAS  Google Scholar 

  17. Newcomer JW, Campos JA, Marcus RN, et al.: A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008, 69:1046–1056.

    PubMed  CAS  Google Scholar 

  18. Muzina DJ, Momah C, Eudicone JM, et al.: Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract 2008, 62:679–687.

    Article  PubMed  CAS  Google Scholar 

  19. De Hert M, Hanssens L, van Winkel R, et al.: A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007, 33:823–830.

    Article  PubMed  Google Scholar 

  20. Basson BR, Kinon BJ, Taylor CC, et al.: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001, 62:231–238.

    PubMed  CAS  Google Scholar 

  21. Street JS, Clark WS, Gannon KS, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000, 57:968–976.

    Article  PubMed  CAS  Google Scholar 

  22. Wilson MM, Vaswani S, Liu D, et al.: Prevalence and causes of undernutrition in medical outpatients. Am J Med 1998, 104:56–63.

    Article  PubMed  CAS  Google Scholar 

  23. Sempos CT, Cleeman JI, Carroll MD, et al.: Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993, 269:3009–3014.

    Article  PubMed  CAS  Google Scholar 

  24. Kennedy JS, Bymaster FP, Schuh L, et al.: A current review of olanzapine’s safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry 2001, 16(Suppl 1):S33–S61.

    Article  PubMed  Google Scholar 

  25. Birkenaes AB, Birkeland KI, Engh JA, et al.: Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008, 28:132–137.

    PubMed  CAS  Google Scholar 

  26. Kelly DL, Conley RR, Love RC, et al.: Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine. Ann Clin Psychiatry 2008, 20:71–78.

    PubMed  Google Scholar 

  27. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity and Diabetes: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596–601.

    Article  Google Scholar 

  28. Koller EA, Cross JT, Doraiswamy PM, Schneider BS: Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003, 23:735–744.

    Article  PubMed  CAS  Google Scholar 

  29. Guo JJ, Keck PE, Corey-Lisle PK, et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested casecontrol study. Pharmacotherapy 2007, 27:27–35.

    Article  PubMed  CAS  Google Scholar 

  30. van Winkel R, De Hert M, Wampers M, et al.: Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008, 69:472–479.

    Article  PubMed  Google Scholar 

  31. Newcomer JW, Haupt DW, Fucetola R, et al.: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002, 59:337–345.

    Article  PubMed  CAS  Google Scholar 

  32. Spurling RD, Lamberti JS, Olsen D, et al.: Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007, 68:406–409.

    PubMed  CAS  Google Scholar 

  33. Lamberti JS, Olson D, Crilly JF, et al.: Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006, 163:1273–1276.

    Article  PubMed  Google Scholar 

  34. Meyer JM, Davis VG, McEvoy JP, et al.: Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008, 103:104–109.

    Article  PubMed  Google Scholar 

  35. Yumru M, Savas HA, Kurt E, et al.: Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007, 98:247–252.

    Article  PubMed  CAS  Google Scholar 

  36. Meyer JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapinetreated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002, 63:425–433.

    PubMed  CAS  Google Scholar 

  37. Meyer JM, Pandina G, Bossie CA, et al.: Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005, 27:1930–1941.

    Article  PubMed  CAS  Google Scholar 

  38. Guo JJ, Keck PE, Corey-Lisle PK, et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J Clin Psychiatry 2006, 67:1055–1061.

    Article  PubMed  CAS  Google Scholar 

  39. Correll CU, Frederickson AM, Kane JM, Manu P: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007, 89:91–100.

    Article  PubMed  Google Scholar 

  40. Gupta S, Masand PS, Virk S, et al.: Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 2004, 70:57–62.

    Article  PubMed  Google Scholar 

  41. Brown RR, Estoup MW: Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005, 20:105–112.

    Article  PubMed  Google Scholar 

  42. Simpson GM, Glick ID, Weiden PJ, et al.: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004, 161:1837–1847.

    Article  PubMed  Google Scholar 

  43. Rossi A, Vita A, Tiradritti P, Romeo F: Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 2008, 23:216–222.

    Article  PubMed  Google Scholar 

  44. Park S, Park H, Togo F, et al.: Year-long physical activity and metabolic syndrome in older Japanese adults: cross-sectional data from the Nakanojo Study. J Gerontol A Biol Sci Med Sci 2008, 63:1119–1123.

    PubMed  Google Scholar 

  45. Stewart KJ, Bacher AC, Turner K, et al.: Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med 2005, 28:9–18.

    Article  PubMed  Google Scholar 

  46. McLaughlin T, Carter S, Lamendola C, et al.: Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr 2006, 84:813–821.

    PubMed  CAS  Google Scholar 

  47. Aleixandre A, Miguel M: Dietary fiber in the prevention and treatment of metabolic syndrome: a review. Crit Rev Food Sci Nutr 2008, 48:905–912.

    Article  PubMed  Google Scholar 

  48. Chen CH, Chiu CC, Huang MC, et al.: Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:925–931.

    Article  PubMed  CAS  Google Scholar 

  49. Wu RR, Zhao JP, Jin H, et al.: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008, 299:185–193.

    Article  PubMed  CAS  Google Scholar 

  50. Ojala K, Repo-Tiihonen E, Tiihonen J, Niskanen L: Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol 2008, 22:33–38.

    Article  PubMed  CAS  Google Scholar 

  51. Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209–1223.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCLA Semel Institute, MC 175919, 760 Westwood Plaza, B8-233B NPI, Los Angeles, CA, 90024, USA

    John O. Brooks III

Authors
  1. John O. Brooks III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hye-Sang Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olya Krasnykh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John O. Brooks III.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brooks, J.O., Chang, HS. & Krasnykh, O. Metabolic risks in older adults receiving second-generation antipsychotic medication. Curr Psychiatry Rep 11, 33–40 (2009). https://doi.org/10.1007/s11920-009-0006-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-009-0006-0

Keywords

Search

Navigation